Genetic Variability of the mTOR Pathway and Prostate Cancer Risk in the European Prospective Investigation on Cancer (EPIC)
View/ Open
Author
Campa, Daniele
Stein, Angelika
Dostal, Lucie
Boeing, Heiner
Pischon, Tobias
Roswall, Nina
Overvad, Kim
Barricarte, Aurelio
Khaw, Kay-Tee
Wareham, Nicholas
Travis, Ruth C.
Allen, Naomi E.
Trichopoulou, Antonia
Palli, Domenico
Sieri, Sabina
Tumino, Rosario
Sacerdote, Carlotta
van Kranen, Henk
Bueno-de-Mesquita, H. Bas
Johansson, Mattias
Romieu, Isabelle
Jenab, Mazda
Siddiq, Afshan
Riboli, Elio
Canzian, Federico
Kaaks, Rudolf
Agoulnik, Irina
Hüsing, Anna
Tjønnelan, Anne
Østergaard, Jane Nautrup
Rodríguez, Laudina
Sala, Núria
Sánchez, Maria-José
Larrañaga, Nerea
Huerta, José-Maria
Hallmans, Göran
Cox, David G.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1371/journal.pone.0016914Metadata
Show full item recordCitation
Campa, Daniele, Anika Hüsing, Angelika Stein, Lucie Dostal, Heiner Boeing, Tobias Pischon, Anne Tjønneland et al. 2011. Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC). PLoS ONE 6(2): e16914Abstract
The mTOR (mammalian target of rapamycin) signal transduction pathway integrates various signals, regulating ribosome biogenesis and protein synthesis as a function of available energy and amino acids, and assuring an appropriate coupling of cellular proliferation with increases in cell size. In addition, recent evidence has pointed to an interplay between the mTOR and p53 pathways. We investigated the genetic variability of 67 key genes in the mTOR pathway and in genes of the p53 pathway which interact with mTOR. We tested the association of 1,084 tagging SNPs with prostate cancer risk in a study of 815 prostate cancer cases and 1,266 controls nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). We chose the SNPs (n = 11) with the strongest association with risk (p<0.01) and sought to replicate their association in an additional series of 838 prostate cancer cases and 943 controls from EPIC. In the joint analysis of first and second phase two SNPs of the PRKCI gene showed an association with risk of prostate cancer (\(OR_{allele}\) = 0.85, 95% CI 0.78–0.94, p = 1.3×\(10^{−3}\) for rs546950 and (\(OR_{allele}\) = 0.84, 95% CI 0.76–0.93, p = 5.6×\(10^{−4}\) for rs4955720). We confirmed this in a meta-analysis using as replication set the data from the second phase of our study jointly with the first phase of the Cancer Genetic Markers of Susceptibility (CGEMS) project. In conclusion, we found an association with prostate cancer risk for two SNPs belonging to PRKCI, a gene which is frequently overexpressed in various neoplasms, including prostate cancer.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044148/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:10483426
Collections
- SPH Scholarly Articles [6362]
Contact administrator regarding this item (to report mistakes or request changes)